Skip to main contentAI and Advanced
/
NATCAPSUQ · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
NA
NSE · Equity shares · Biotechnology & Drugs10.80 · 5.00%
Natural Capsules NATCAPSUQ
NSE:INR 226.98
BSE:INR 176.1
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for NATCAPSUQ
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 216.18
Day rangeINR 218.5 — INR 226.98
52-week rangeINR 137.5 — INR 296.4
Volume18,619
Market cap149.92
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)187.2
Net Income (INR Cr)-17.07
Rev Growth (5 Year %)18.68
Book Value213.4
EPS-23.84
Price/BV1.06Computed
Research path: Interpret Natural Capsules's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
NATCAPSUQNatural Capsules1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 424.16 | 419.35 | 376.53 |
| Cash Equivalents | 4.82 | 0 | 0 |
| Other Liabilities Total | 1.26 | 0.52 | 0 |
| Long Term Debt | 54.72 | 56.4 | 67.93 |
| Common Stock Total | 10.39 | 10.34 | 9.33 |
| Other Equity Total | 0 | -0.19 | 0.2 |
| Other Current Assets Total | 34.3 | 0.74 | 0.88 |
| Total Assets | 424.16 | 419.35 | 376.53 |
| Current Portof LT Debt/Capital Leases | 60.03 | 10.82 | 11.04 |
| Total Equity | 221.64 | 232.94 | 203.8 |
| Long Term Investments | 6.71 | 2.73 | 2.73 |
| Retained Earnings(Accumulated Deficit) | 211.25 | 83.27 | 81.51 |
| Total Common Shares Outstanding | 1.04 | 1.03 | 0.93 |
| Tangible Book Valueper Share Common Eq | 213.4 | 180.12 | 168.06 |
| Total Liabilities | 202.52 | 186.42 | 172.73 |
| Total Debt | 115.48 | 105.19 | 109.01 |
| Cashand Short Term Investments | 4.82 | 5.2 | 12.96 |
| Total Receivables Net | 71.35 | 93.59 | 86.48 |
| Accounts Receivable-Trade Net | 71.35 | 62.24 | 54.47 |
| Property/Plant/Equipment Total-Net | 278.02 | 283.63 | 246.1 |
| Minority Interest | 13.09 | 24.22 | 25 |
| Total Current Liabilities | 132.73 | 99.99 | 76.47 |
| Total Inventory | 26.33 | 29.52 | 23.2 |
| Accounts Payable | 55.32 | 38.51 | 30.42 |
| Other Currentliabilities Total | 17.37 | 13.72 | 4.99 |
| Total Long Term Debt | 55.44 | 57.43 | 67.95 |
| Other Long Term Assets Total | 2.63 | 2.62 | 2.48 |
| Total Current Assets | 136.8 | 129.59 | 123.77 |
| Capital Lease Obligations | 0.72 | 1.02 | 0.01 |
| Accumulated Depreciation Total | Not available | -68.45 | -59.8 |
| Preferred Stock-Non Redeemable Net | Not available | 46.67 | 46.67 |
| Prepaid Expenses | Not available | 0.53 | 0.25 |
| Additional Paid-In Capital | Not available | 92.86 | 66.09 |
| Cash | Not available | 5.2 | 12.96 |
| Property/Plant/Equipment Total-Gross | Not available | 352.08 | 162.09 |
| Notes Payable/Short Term Debt | Not available | 36.95 | 30.02 |
| Deferred Income Tax | Not available | 4.25 | 3.3 |
| Intangibles Net | Not available | 0 | 0.48 |
| Note Receivable-Long Term | Not available | 0.78 | 0.98 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %64.35
Margins
Operating Margin 12m-9.99
Operating Margin 5y Avg5.84
Net Profit Margin 12m-13.17
Net Profit Margin 5y1.69
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio0.80
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk48.14
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,935.8 | 4.64 L | 38.4 | — |
| Divi's Laboratories | INR 7,376.6 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,975 | 1.68 L | 72.73 | — |
| Cipla | INR 1,405.9 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,117.55 | 1.11 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 50.92%
- Other
- 49.08%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Natural Capsules Reports FY26 Standalone Profit, Consolidated Loss Amid API Facility Investment - WhalesbookMarket news · 17 Jul 2026, 10:11 pm
Natural Capsules Reports FY26 Standalone Profit, Consolidated Loss Amid API Facility Investment Whalesbook
Natural Capsules to hold 33rd AGM on Aug 12 via VC - scanx.tradeMarket news · 17 Jul 2026, 2:16 pm
Natural Capsules to hold 33rd AGM on Aug 12 via VC scanx.trade
Endura Naturals Male Enhancement Video Review: What the Footage Shows and What It Misses - KMUMarket news · 15 Jul 2026, 10:44 am
Endura Naturals Male Enhancement Video Review: What the Footage Shows and What It Misses KMU
Natural Capsules subsidiary allots 1.11 lakh rights shares - scanx.tradeMarket news · 12 Jul 2026, 12:30 pm
Natural Capsules subsidiary allots 1.11 lakh rights shares scanx.trade
The Rock Testo Pills: A Realistic Look at Testosterone Support Supplements - KMUMarket news · 12 Jul 2026, 4:57 am
The Rock Testo Pills: A Realistic Look at Testosterone Support Supplements KMU
FSSAI issues notice to FBOs selling paneer, juice capsules, and chocolate spread over misleading claims - The New Indian ExpressMarket news · 6 Jul 2026, 6:56 pm
FSSAI issues notice to FBOs selling paneer, juice capsules, and chocolate spread over misleading claims The New Indian Express
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsAudited Results
Rusaka Markets Community
Discussion and sentiment for Natural Capsules
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Natural Capsules Limited is an India-based hard capsule shell manufacturer, specialized in manufacturing an array of capsules, including hard gelatin capsules, vegetarian capsules, and various specialty variants. The Company offers a diverse range of capsule products to both domestic and international markets, serving the pharmaceutical and nutraceutical industries. Its offerings include hard gelatin capsules, hydroxypropyl methylcellulose (HPMC) vegetarian capsules and others, including shiny capsules, sweet capsules, fast-release capsules, regulatory variants, sodium laureth sulfate (SLS) free capsules, preservative free capsules and transmissible spongiform encephalopathy (TSE) free capsules. The Company, through its subsidiary, Natural Biogenex Private Limited, is focused on manufacturing APIs such as prednisolone, betamethasone, dexamethasone, and hydrocortisone along with their derivatives. It has two manufacturing facilities that are located in Bengaluru and Puducherry.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- NATCAPSUQ
- BSE Code
- 524654
Questions
Stock FAQ
What is the symbol and ISIN of Natural Capsules?
Natural Capsules has the symbol NATCAPSUQ and ISIN - INE936B01015.
What is the current price of Natural Capsules?
Natural Capsules is currently trading at INR 226.98.
What are the year high and year low of Natural Capsules?
Natural Capsules has a year high of INR 296.40 and a year low of INR 137.50.
What is the market capitalization of Natural Capsules?
Natural Capsules has a market capitalization of INR 149.92 crore.
What is the P/E ratio of Natural Capsules?
Natural Capsules has a P/E ratio of NA.
What is the dividend yield of Natural Capsules?
Natural Capsules has a dividend yield of 0.00%.
How is the financial performance of Natural Capsules based on revenue, net income, and EPS?
Natural Capsules has revenue of INR 187.20 crore, net income of INR -17.07 crore, and EPS of INR -23.86.
What is the book value of Natural Capsules?
Natural Capsules has a book value of INR 213.40.
What is the debt-to-equity ratio of Natural Capsules?
Natural Capsules has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Natural Capsules?
Natural Capsules has a price-to-book ratio of 1.06 and a price-to-sales ratio of 0.80.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.